Company: PSTV
Filing Date: 2025-03-14
Form Type: PRE 14A
Source: 0001140361-25-008857
Chunk: 21

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-14
Form: PRE 14A
Chunk 21
---
 the State of Delaware of the certificate of amendment, even if the authority to effect these amendments is approved by our stockholders at the Special Meeting. By voting in favor of the Reverse Stock Split (including each of the fixed reverse stock split ratios), you are expressly also authorizing the Board to delay, not proceed with, and abandon, the Reverse Stock Split (including all of the fixed reverse stock split ratios) and the certificate of amendment if it should so decide, in its sole discretion, that such actions are in the best interests of our stockholders.

**Interests of Officers and Directors in this Proposal

Our officers and directors do not have any substantial interest, direct or indirect, in this proposal.**

#### Vote required
Approval of Proposal No. 1 requires the affirmative vote of a majority of the outstanding shares of Common Stock entitled to vote on the proposal. Abstentions will have the effect of a vote “AGAINST” this proposal.

#### Board Recommendation
**OUR BOARD UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THIS PROPOSAL NO. 1 TO APPROVE THE REVERSE STOCK SPLIT.**

<div align='center'>12</div>

TABLE OF CONTENTS

PROPOSAL 2: THE ISSUANCE PROPOSAL On March 4, 2025, the Company consummated the previously announced private placement (the “Private Placement”) pursuant to that certain securities purchase agreement (“Purchase Agreement”) with accredited investors, including certain existing stockholders of the Company (collectively, the “Purchasers”). The Purchase Agreement provided for the sale and issuance by the Company of an aggregate of 28,042,140 shares of the Company’s Common Stock, or, at the election of each Purchaser, prefunded warrants to purchase Common Stock (the “Prefunded Warrants”), exercisable immediately at an exercise price of $0.001 per share, with each share of Common Stock or Prefunded Warrant accompanied by (i) one Series A common warrant (the “Series A Warrants”) to purchase one share of Common Stock (the “Series A Warrant Shares”), and (ii) one Series B common warrant to purchase one share of Common Stock (the “Series B Warrant Shares”). The combined purchase price of $0.66 for each share of Common Stock or $0.659 for each Prefunded Warrant in the Private Placement, together with one accompanying Series A Warrant and one accompanying Series B Warrant, represented the applicable